Concepedia

Yali Zhu

YZ

Statistics

Publications

45

Citations

2.1K

H-Index

24

Active since

2002

Affiliations

The Ohio State University(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Guangzhou Medical University

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Yali Zhu is an author at The Ohio State University specializing in pharmacology, medicine, and life sciences.

Publications per year

2002–2022

45

Publications

45

Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects

James E. Patrick, Teddy Kosoglou, Kathe Stauber et al. · Drug Metabolism and Disposition · 2002 · 165 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

Monica Mita, Anil A. Joy, Alain C. Mita et al. · Clinical Breast Cancer · 2013 · 153 citations

Medicine, Oncology, Pharmacology +17

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

John Nemunaitis, Karen Small, Paul T. Kirschmeier et al. · Journal of Translational Medicine · 2013 · 129 citations · Full text

Medicine, Oncology, Pharmacology +17

Movement of Potato Spindle Tuber Viroid Reveals Regulatory Points of Phloem-Mediated RNA Traffic

Yali Zhu, Yijun Qi, Yan Xun et al. · PLANT PHYSIOLOGY · 2002 · 106 citations · Full text

Life Sciences, Plant Biology, Plant Sciences +17

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

Sunil Sharma, Nancy E. Kemeny, David P. Kelsen et al. · Annals of Oncology · 2002 · 104 citations

Medicine, Oncology, Pharmacology +13

1–5 of 45